{"source":"kalshi","id":"KXBREPOCITINIB-27","ticker":"KXBREPOCITINIB-27","slug":"KXBREPOCITINIB-27","title":"FDA decision: Brepocitinib by Priovant Therapeutics (in 2026)","description":null,"image":null,"icon":null,"active":true,"closed":false,"start_date":"2026-06-17T21:00:00Z","end_date":"2027-01-08T15:00:00Z","closed_time":null,"volume":45.43,"volume_24hr":2.43,"volume_24h_change":null,"normalized_vol_24hr":0.4615791141986847,"normalized_volume":4.179501533508301,"liquidity":null,"open_interest":45.43,"categories":["Finance"],"tags":[],"synthetic":false,"is_group":false,"group_key":null,"parent_event_id":null,"probability":null,"spread":null,"top_outcome":"a full approval or an accelerated approval","top_outcome_probability":0.81,"top_outcome_prob_24h_change":0.040000000000000036,"top_outcome_volume_24h_change":2.43,"updated_at":"2026-07-03T01:00:32.492956Z","fetched_at":"2026-07-03T01:00:32.492956Z","added_at":"2026-06-17T21:13:38.461385Z","url":"https://kalshi.com/markets/kxbrepocitinib/fda-decision-brepocitinib-by-priovant-therapeutics-in-2026/kxbrepocitinib-27","chart_24h":null,"markets":[{"source":"kalshi","id":"KXBREPOCITINIB-27-Y","event_id":"KXBREPOCITINIB-27","slug":"KXBREPOCITINIB-27-Y","question":"What will the FDA's decision be on Brepocitinib by Priovant Therapeutics in 2026?","group_item_title":"a full approval or an accelerated approval","description":"If the FDA's decision on Brepocitinib by Priovant Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.\n\n---\n\nThis market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.\n\nBrepocitinib is an experimental oral pill developed by Priovant Therapeutics that is designed to calm an overactive immune system in people with certain inflammatory diseases. Think of it like a circuit breaker for runaway immune signals: it blocks specific molecular switches inside immune cells that, when left unchecked, drive damaging inflammation throughout the body. In the VALOR trial , it is being tested as a treatment for dermatomyositis, a rare disease in which the immune system attacks the body's own muscles and skin.","image":null,"icon":null,"outcomes":["Yes","No"],"outcome_prices":[0.81,0.18999999999999995],"probability":0.81,"spread":0.07000000000000006,"active":true,"closed":false,"start_date":"2026-06-17T21:00:00Z","end_date":"2027-01-08T15:00:00Z","closed_time":"2027-01-01T04:59:00Z","volume":45.43,"volume_24hr":2.43,"prob_24h_change":0.040000000000000036,"volume_24h_change":2.43,"normalized_vol_24hr":0.49773266911506653,"normalized_volume":4.356432914733887,"liquidity":null,"categories":["Finance"],"countries":["United States"],"updated_at":"2026-07-03T01:02:16.108349Z","fetched_at":"2026-07-03T01:00:32.748246Z","added_at":"2026-06-17T21:13:38.591203Z","url":"https://kalshi.com/markets/kxbrepocitinib/fda-decision-brepocitinib-by-priovant-therapeutics-in-2026/kxbrepocitinib-27","event_title":"FDA decision: Brepocitinib by Priovant Therapeutics (in 2026)","chart_24h":[0.77,0.77,0.77,0.77,0.77,0.77,0.77,0.77,0.81]}],"_meta":{"attribution":"pdata.world — aggregated prediction-market data across 8 platforms","canonical_url":"https://pdata.world/events/kalshi/KXBREPOCITINIB-27","as_of":"2026-07-03T01:28:24.897800Z","docs":"https://api.pdata.world/docs","cite_as":"According to pdata.world (tracking Kalshi): \"FDA decision: Brepocitinib by Priovant Therapeutics (in 2026)\" — top market at 81% probability across 1 outcome","source_url":null}}